Abstract
Relugolix 40 mg is a non-peptide gonadotropin-releasing hormone receptor antagonist being developed for use in combination with estradiol 1 mg and norethindrone acetate 0.5 mg (relugolix combination therapy; Rel-CT) to treat heavy menstrual bleeding (HMB) associated with uterine fibroids (UF). The rationale for combination therapy is to mitigate anticipated hypoestrogenic effects with relugolix monotherapy, including bone loss. Rel-CT preserved bone mineral density (BMD) in the pivotal LIBERTY 1/2 trials and Long-Term Extension (LTE) study.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
